Pascal Soriot, AstraZeneca CEO (Raphael Lafargue/Abaca/Sipa USA(Sipa via AP Images)

Covid-19 roundup: As­traZeneca launch­es 3rd US PhI­II vac­cine study with a vow to avoid 'cut­ting cor­ner­s'

As­traZeneca has launched the fi­nal round of US test­ing for their close­ly-watched Ox­ford vac­cine for Covid-19, tak­ing the third spot in line just be­hind Mod­er­na and the Pfiz­er/BioN­Tech team.

As they an­nounced the move, As­traZeneca CEO Pas­cal So­ri­ot stopped for a mo­ment to high­light the prin­ci­ples they fol­low in drug and vac­cine de­vel­op­ment — of­fer­ing some re­as­sur­ances on R&D val­ues in the wake of the pan­de­mo­ni­um that has erupt­ed in the US fol­low­ing the plas­ma fi­as­co, as Pres­i­dent Trump and FDA com­mis­sion­er Stephen Hahn tout­ed mis­lead­ing in­for­ma­tion on plas­ma’s ef­fi­ca­cy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.